Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / y mabs inks contract with wep for early access for c

YMAB - Y-mAbs inks contract with WEP for early access for cancer drug Danyelza in Europe

Y-mAbs Therapeutics Inc.

  • Y-mAbs Therapeutics ( NASDAQ: YMAB ) said it signed a distribution agreement with WEP Clinical for an early access program for its neuroblastoma drug Danyelza (naxitamab-gqgk) 40mg/10mL Injection in Europe.
  • Neuroblastoma is a cancer which develops from immature nerve cells found in several parts of the body.
  • "Initially, DANYELZA will be available through such program in Spain and France, and we hope to add additional territories to the agreement," said Thomas Gad, founder, president and interim CEO.
  • Y-mAbs has licensed the monoclonal antibody therapy Danyelza from the Memorial Sloan Kettering Cancer Center.

For further details see:

Y-mAbs inks contract with WEP for early access for cancer drug Danyelza in Europe
Stock Information
Company Name: Y-mAbs Therapeutics Inc.
Stock Symbol: YMAB
Market: NASDAQ
Menu
YMAB YMAB Quote YMAB Short YMAB News YMAB Articles YMAB Message Board
Get YMAB Alerts

News, Short Squeeze, Breakout and More Instantly...